Comparative Pharmacology
Head-to-head clinical analysis: OXILAN 300 versus RENORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXILAN 300 versus RENORMAX.
OXILAN-300 vs RENORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays and enhances vascular and tissue visualization during imaging procedures.
Selective beta-1 adrenergic receptor antagonist; reduces cardiac output, heart rate, and blood pressure by blocking catecholamine effects on cardiac beta-1 receptors.
Intravenous: 1-2 mL/kg (300 mg iodine/mL) for contrast imaging; maximum dose 2 mL/kg per procedure.
5 mg intravenously every 12 hours
None Documented
None Documented
Terminal half-life: 1.5–2.5 hours (normal renal function); prolonged in renal impairment (up to 30 hours in severe impairment).
Terminal elimination half-life: 8-10 hours in healthy adults. Prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min). Provides basis for twice-daily dosing in normal renal function.
Renal elimination: 100% unchanged via glomerular filtration; biliary/fecal excretion negligible (<1%).
Primarily renal (60-70% unchanged; 10-15% as glucuronide conjugate); biliary/fecal (5-10%); 80-85% total recovered in urine and feces within 72 hours.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent